SG190921A1 - Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases - Google Patents

Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases Download PDF

Info

Publication number
SG190921A1
SG190921A1 SG2013041439A SG2013041439A SG190921A1 SG 190921 A1 SG190921 A1 SG 190921A1 SG 2013041439 A SG2013041439 A SG 2013041439A SG 2013041439 A SG2013041439 A SG 2013041439A SG 190921 A1 SG190921 A1 SG 190921A1
Authority
SG
Singapore
Prior art keywords
hydroxylamine
propylamino
bis
triazin
methyl
Prior art date
Application number
SG2013041439A
Other languages
English (en)
Inventor
Scott L Dax
Richard Woodward
Sean Peng
Original Assignee
Galleon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galleon Pharmaceuticals Inc filed Critical Galleon Pharmaceuticals Inc
Publication of SG190921A1 publication Critical patent/SG190921A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/04—Tracheal tubes
    • A61M16/0465—Tracheostomy tubes; Devices for performing a tracheostomy; Accessories therefor, e.g. masks, filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/06—Respiratory or anaesthetic masks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/66—Derivatives of melamine in which a hetero atom is directly attached to a nitrogen atom of melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG2013041439A 2010-11-29 2011-11-29 Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases SG190921A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41777710P 2010-11-29 2010-11-29
US201161494268P 2011-06-07 2011-06-07
PCT/US2011/062386 WO2012074999A1 (en) 2010-11-29 2011-11-29 Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases

Publications (1)

Publication Number Publication Date
SG190921A1 true SG190921A1 (en) 2013-07-31

Family

ID=46162783

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013041439A SG190921A1 (en) 2010-11-29 2011-11-29 Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
SG10201601507YA SG10201601507YA (en) 2010-11-29 2011-11-29 Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201601507YA SG10201601507YA (en) 2010-11-29 2011-11-29 Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases

Country Status (11)

Country Link
US (2) US9351972B2 (enExample)
EP (1) EP2646423A4 (enExample)
JP (1) JP5907986B2 (enExample)
KR (1) KR20140049961A (enExample)
CN (1) CN103347866B (enExample)
AU (1) AU2011336764B2 (enExample)
BR (1) BR112013013429A2 (enExample)
CA (1) CA2819333A1 (enExample)
SG (2) SG190921A1 (enExample)
WO (1) WO2012074999A1 (enExample)
ZA (1) ZA201303960B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
NZ597379A (en) 2009-06-29 2014-04-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
EP3064595B1 (en) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Methods for cell-proliferation-related disorders
PH12017501176B1 (en) 2011-05-03 2023-03-08 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
KR20140059246A (ko) 2011-09-22 2014-05-15 화이자 인코포레이티드 피롤로피리미딘 및 퓨린 유도체
AU2013207289B2 (en) 2012-01-06 2017-09-21 Les Laboratoires Servier Therapeutically active compounds and their methods of use
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
AU2013267570A1 (en) * 2012-05-29 2014-12-18 Galleon Pharmaceuticals, Inc. Novel compounds and compositions for treatment of breathing control disorders or diseases
WO2014062511A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
BR112015011213A2 (pt) * 2012-11-15 2017-08-29 Galleon Pharmaceuticals Inc Composto, composição farmacêutica, método de prevenção ou tratamento de um distúrbio ou doença de controle respiratório em um indivíduo, método de prevenção de desestabilização ou de estabilização do ritmo respiratório em um indivíduo, método de preparação de o,n-dimetil-n-[4-(n-propilamina)-6-(prop-2-inilamina)-[1,3,5]triazin-2-il]-hidroxilamina, e composição.
US9643971B2 (en) * 2013-03-15 2017-05-09 Galleon Pharmaceuticals, Inc. Breathing control modulating compounds, and methods of using same
EP3019490B1 (en) 2013-07-11 2020-06-03 Agios Pharmaceuticals, Inc. N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2917671A1 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
KR20220070066A (ko) 2014-03-14 2022-05-27 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
SI3307271T1 (sl) 2015-06-11 2023-11-30 Agios Pharmaceuticals, Inc. Postopki za uporabo aktivatorjev piruvat kinaze
JP6731427B2 (ja) * 2015-06-30 2020-07-29 ネウラッド リミテッドＮｅｕｒａｄ Ｌｔｄ． 新規の呼吸制御調節化合物、およびこれを製造し、かつ使用する方法
US10653710B2 (en) 2015-10-15 2020-05-19 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
PT3362065T (pt) 2015-10-15 2024-06-21 Servier Lab Terapia de combinação compreendendo ivosidenib, citarabina e daunorubicina ou idarubicina para o tratamento de leucemia mielóide aguda
CA3087881A1 (en) 2017-01-17 2018-07-26 Michael David FORREST Therapeutic inhibitors of the reverse mode of atp synthase
BR112019028172A2 (pt) 2017-07-13 2020-10-06 Michael David Forrest moduladores terapêuticos do modo reverso da atp sintase
JP7313341B2 (ja) * 2017-09-28 2023-07-24 コーニンクレッカ フィリップス エヌ ヴェ 圧力支援治療中に患者の脳卒中を検出するシステム及び方法
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN114173872A (zh) * 2019-05-22 2022-03-11 依那拉治疗股份有限公司 治疗药物过量的方法和药物组合物
WO2022235771A1 (en) * 2021-05-04 2022-11-10 Enalare Therapeutics Inc. Large-conductance potassium channel modulators, compositions thereof, methods of manufacturing thereof, and methods of use thereof
CA3236586A1 (en) 2021-11-02 2023-05-11 Joseph Pergolizzi Methods of treating respiratory depression modulated by a non-opioid agent
MX2024008162A (es) * 2021-12-27 2024-09-17 Enalare Therapeutics Inc Formulaciones parenterales estimulantes respiratorias.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
GB1001665A (en) 1961-06-05 1965-08-18 American Cyanamid Co Triazine derivatives and process for their preparation
CA2067221C (en) 1989-10-11 1997-04-15 Yasuji Sakuma Fused pyrimidine derivative, process for preparation of same and pharmaceutical preparation comprising same as active ingredient
JPH08272059A (ja) 1995-03-31 1996-10-18 Fuji Photo Film Co Ltd 多層ハロゲン化銀カラー写真感光材料包装体
JPH09189973A (ja) * 1996-01-08 1997-07-22 Fuji Photo Film Co Ltd ハロゲン化銀乳剤及びこれを用いる写真感光材料
JPH09251197A (ja) 1996-03-15 1997-09-22 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH09304898A (ja) 1996-05-15 1997-11-28 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
ATE377003T1 (de) * 1999-01-22 2007-11-15 Elan Pharm Inc Verbindungen die die vla-4 vermittelte adhäsion von leukozyten inhibieren
US6525067B1 (en) * 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
US20020065270A1 (en) * 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
JP2003519143A (ja) * 1999-12-28 2003-06-17 ファーマコピーア，インコーポレーティッド ピリミジン及びトリアジン系キナーゼ阻害剤
ATE458724T1 (de) * 2001-06-26 2010-03-15 Bristol Myers Squibb Co N-heterocyclische inhibitoren der expression von tnf-alpha
RS34004A (sr) * 2001-09-21 2006-10-27 Reddy Us Therapeutics Inc. Postupci i sastavi novih triazin jedinjenja
US20030168629A1 (en) 2001-12-10 2003-09-11 Lazar Warren G. Reactive liquid polymer crosslinking agent and process for preparation
PL215168B1 (pl) 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
CA2484921A1 (en) 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
EP1572097A4 (en) 2002-09-30 2010-02-17 Smithkline Beecham Corp NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF INFECTIONS WITH THE HEPATITIS C-VIRUS
US7384937B2 (en) 2002-11-06 2008-06-10 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
AU2004259346A1 (en) 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
CN1926140A (zh) * 2004-03-05 2007-03-07 大正制药株式会社 吡咯并嘧啶衍生物
JP2007529606A (ja) * 2004-03-15 2007-10-25 ハネウェル・インターナショナル・インコーポレーテッド セルロース強化樹脂組成物
WO2006023702A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders with setiptiline
CN101495464B (zh) * 2005-12-29 2014-03-05 詹森药业有限公司 激肽原1受体拮抗剂
US8227466B2 (en) * 2006-05-17 2012-07-24 Albert Einstein College Of Medicine Of Yeshiva University Prostaglandin transporter inhibitors
GB0610317D0 (en) 2006-05-24 2006-07-05 Medical Res Council Antiparasitic compounds and compositions
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
JP2009545598A (ja) * 2006-08-01 2009-12-24 プリーシス・ファーマシューティカルズ・インコーポレイテッド Ｐ３８キナーゼ阻害剤
US20080119457A1 (en) 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
WO2008105968A1 (en) 2006-11-03 2008-09-04 Smithkline Beecham Corporation Novel seh inhibitors and their use
WO2009115084A2 (de) 2008-03-20 2009-09-24 Schebo Biotech Ag Neue pyrrolopyrimidin-derivate und deren verwendungen
CN101885707B (zh) * 2009-05-15 2012-08-29 中国科学院化学研究所 三嗪类衍生物及其制备方法与作为杀虫剂的用途

Also Published As

Publication number Publication date
BR112013013429A2 (pt) 2017-03-21
SG10201601507YA (en) 2016-04-28
CN103347866A (zh) 2013-10-09
KR20140049961A (ko) 2014-04-28
US20120142647A1 (en) 2012-06-07
EP2646423A1 (en) 2013-10-09
WO2012074999A1 (en) 2012-06-07
CN103347866B (zh) 2016-05-18
JP2013544285A (ja) 2013-12-12
ZA201303960B (en) 2014-07-30
JP5907986B2 (ja) 2016-04-26
AU2011336764A1 (en) 2013-06-20
AU2011336764B2 (en) 2017-02-23
US20160256463A1 (en) 2016-09-08
EP2646423A4 (en) 2014-04-30
US9351972B2 (en) 2016-05-31
CA2819333A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
AU2011336764B2 (en) Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
US9162992B2 (en) Compounds and compositions for treatment of breathing control disorders or diseases
RU2734506C2 (ru) Новые модулирующие регуляцию дыхания соединения и способы их получения и применения
KR20150082633A (ko) 경구적으로 생체이용가능한 신규 호흡 조절 제어 화합물 및 그의 사용 방법
EP4501925A1 (en) Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof
AU2013267570A1 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases
NZ738082B2 (en) Novel breathing control modulating compounds, and methods of making and using same
BR112017028487B1 (pt) Composto de modulação do controle da respiração e composição farmacêutica